GET DAILY SIGNALSSolventum (SOLV) Delivers Q3 EPS Beat and Raises Full-Year Guidance
Key Takeaways
- Solventum reported third-quarter 2026 revenue of $1.95 billion, down 7% year over year but modestly above the $1.93 billion consensus estimate.
- Adjusted earnings per share (EPS, a company's profit divided by its outstanding shares) came in at $1.45, beating analysts' consensus of $1.34 by roughly 8%.
- Organic sales declined 2.8%, reflecting a roughly 630-basis-point (bps, equal to 6.3 percentage points) headwind from advance orders placed ahead of the company's ERP (enterprise resource planning) system cutover.
- Free cash flow turned positive at $97 million, up from negative $21 million in the prior-year quarter.
- Management raised its full-year 2026 adjusted EPS guidance to a midpoint of approximately $7.25.
- For more details on Solventum's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages for up-to-date insights.
- Discover how AI-powered trading tools are scanning the market with Trending AI Robots.
Why This Quarter Matters
Solventum, spun off from 3M in April 2024, operates across medical-surgical supplies, dental solutions, and health information systems. Its results provide an important update on the multi-year separation process from its former parent. The third quarter brought added complexity with the largest ERP cutover in the company's history. Investors are focused on whether margins and cash generation can hold as one-time separation costs decline. With more than 90% of the 3M separation now complete, the report gave a clearer view of the standalone business and its trajectory toward the "RemainCo" structure.
The Reported Numbers
SOLV posted total net sales of $1.95 billion for the third quarter of fiscal 2026, a 7.0% reported decline and slightly above the $1.93 billion consensus. Organic sales fell 2.8%, which management linked mainly to an expected roughly 630-bps impact from advance orders placed ahead of the ERP cutover. Adjusted EPS reached $1.45, beating the $1.34 consensus. On a GAAP basis, the company recorded a net loss of $12 million, or $(0.07) per diluted share, compared with net income of $1,266 million a year earlier that included a gain on the sale of the Purification and Filtration business. Free cash flow improved to $97 million from negative $21 million. Management also raised full-year 2026 adjusted EPS guidance to a midpoint of about $7.25. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction
Shares moved modestly higher right after the release, rising about 1.9% to $86.51. The adjusted EPS beat and raised guidance appeared to outweigh the headline revenue decline. The reaction stayed measured, reflecting the mixed picture of organic sales coming in light while profitability exceeded expectations. Investors seemed to discount the ERP-related order timing effect, which had been flagged in advance. The improvement in free cash flow also stood out, given earlier concerns about cash generation during the post-spin period. Sentiment continues to center on whether SOLV can maintain margin and cash-flow progress as separation costs fade.
Key Themes to Follow
Looking ahead, several areas will shape the next phase for Solventum. Completion of the 3M separation remains important, with management planning to exit the balance of transition service agreements by the end of 2027. Each step should reduce execution risk and support free cash flow.
Portfolio strategy is another focus. Management has outlined a more focused "RemainCo" structure, and updates on that process will help clarify the long-term growth and margin outlook. An Investor Day scheduled for March 2027 may offer additional detail on the remaining business.
Finally, commercial momentum in core areas such as negative pressure wound therapy, IV site management, and sterilization assurance will be worth monitoring, along with the planned launch of Clarity Composite Veneers in early 2027. Margin trends, cost control, and sustained free cash flow improvement will indicate whether recent execution continues.
Streamlining Research with Tickeron Tools
In my own analysis, I frequently rely on Tickeron’s AI Screener to quickly filter stocks and ETFs by technical patterns, fundamentals, and AI-driven signals. It helps surface comparable ideas across sectors and supports more efficient review of earnings-driven moves like the one from SOLV. The customizable filters make it straightforward to benchmark performance and identify potential setups without manual effort.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SOLV's RSI Indicator recovers from oversold territory
The RSI Indicator for SOLV moved out of oversold territory on October 29, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 19 similar instances when the indicator left oversold territory. In 14 of the 19 cases the stock moved higher. This puts the odds of a move higher at 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 18 of 32 cases where SOLV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 56%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on SOLV as a result. In 31 of 47 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
The Moving Average Convergence Divergence (MACD) for SOLV just turned positive on November 04, 2026. Looking at past instances where SOLV's MACD turned positive, the stock continued to rise in 12 of 24 cases over the following month. The odds of a continued upward trend are 50%.
SOLV moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where SOLV advanced for three days, in 99 of 152 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
Bearish Trend Analysis
The 10-day moving average for SOLV crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 2 of 7 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 29%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SOLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
SOLV broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SOLV entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 30 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. SOLV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.169) is normal, around the industry mean (5.069). P/E Ratio (10.857) is within average values for comparable stocks, (40.009). Projected Growth (PEG Ratio) (1.220) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.871) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SOLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsOther
Advertisement